Meeting
2011 ASCO Annual Meeting
COCIS individual patient data (IPD) meta-analysis: Carboplatin- or cisplatin-based chemotherapy (CT) as first-line treatment of small cell lung cancer (SCLC).
Authors
A. Rossi
Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy
A. Rossi , M. Di Maio , P. Chiodini , R. Rudd , H. Okamoto , D. Skarlos , M. Frueh , W. Qian , T. Tamura , E. Samantas , T. Shibata , F. Perrone , C. Gallo , C. Gridelli , O. Martelli , S. M. Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Local-regional and Adjuvant Therapy/Small Cell
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 29: 2011 (suppl; abstr 7022)
Abstract #
7022
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Carboplatin versus cisplatin for the treatment of extensive-stage small cell lung cancer (SCLC): A National VA Database analysis.
First Author: Ibrahim Azar
Poster
2015 ASCO Annual Meeting
A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN).
First Author: Qinyang Li
Poster
2013 ASCO Annual Meeting
Randomized phase III trial of gemcitabine and cisplatin versus gemcitabine alone in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) 2: CAPPA-2 study.
First Author: Alessandro Morabito
Poster
2013 ASCO Annual Meeting
Gemcitabine, paclitaxel, and doxorubicin as first-line therapy for patients with advanced urothelial carcinoma and renal insufficiency: A phase II study.
First Author: Lance C. Pagliaro